Top Stocks That Could Double in 2022

FILE PHOTO: The Wall Street bull statue is pictured in the Manhattan Borough of New York

We’ve dealt with absolute chaos in the markets.

There was the coronavirus, the new variant, geopolitical issues, inflation, fears of Fed action, depressing economic outlooks, you name it…

Now, investors want to know what’s going to happen next.

Unfortunately, we can’t tell you that with 100% certainty. But we can point you in the direction of red hot stocks that could double in the New Year.

Lithium Americas (LAC) 

Lithium Americas could easily see higher highs.

For one, for millions of EVs to hit the roads, each will need around 22 pounds of lithium.

Unfortunately, the world is in short supply, with massive demand.

Even the International Energy Agency is warning that the, “The supply of critical minerals crucial for technologies such as wind turbines and electric vehicles will have to be ramped up over the next decades if the planet’s climate targets are to be met.”

That’s a strong catalyst for Lithium Americas.

Even better, construction activities at Caucharí-Olaroz remain on track to achieve first production by mid-2022 on the initial 40,000 tonnes per annum operation.

Cassava Sciences (SAVA)

Cassava Sciences could be one of the most talked about Alzheimer’s stocks of 2022.

Despite all of the negativity, Cassava pushed forward with Phase III trials.

In October, the company announced it initiated a Phase 3 efficacy study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease, with a second Phase 3 efficacy study of simufilam in Alzheimer’s disease is expected to begin by year end.

Shortly after, SAVA would explode higher.

All after a review by the Journal of Neuroscience showed no evidence of data manipulation with the company’sdrug candidate.

Nowadays, Cassava Sciences’ Phase 3 efficacy studies of simufilam in Alzheimer’s disease are being conducted under Special Protocol Assessments (SPA) from the U.S. Food and Drug Administration (FDA). The SPAs document that FDA has reviewed and agreed upon the key design features of Cassava Sciences’ Phase 3 study protocols.

ChargePoint Holdings Inc. (CHPT)

With the red-hot EV boom accelerating, EV charging stocks, like CHPT are just starting to run.  Helping, the latest infrastructure bill “allocates $5 billion to expand EV-charging stations along highways and an additional $2.5 billion for other charging alternatives such as hydrogen-fueling infrastructure. President Joe Biden said the funding could help build more than 500,000 charging stations, and help make 50% of vehicles electric by 2030,” according to Barron’s.